GLIOMA, MALIGNANT

This early-stage trial tests a vaccine made from small pieces of proteins (peptides) found on glioblastoma cells. The goal is to see if the vaccine is safe and can train the immune system to fight the cancer. The study includes 24 adults with a specific type of newly diagnosed, u…

This early-phase trial tests whether adding the drug AZD1390 to standard radiation therapy can help people with a fast-growing brain cancer called glioblastoma (grade 4 glioma). It includes both newly diagnosed and recurrent patients. The study first checks how much drug reaches …

This study tests a drug called niraparib in people with two types of brain tumors: newly diagnosed glioblastoma and recurrent IDH-mutant glioma with ATRX loss. The goal is to see if the drug reaches the tumor and slows its growth. Up to 42 participants will receive niraparib befo…

This study looks at how the immune system is weakened in people with aggressive brain tumors called gliomas. Researchers will use special MRI scans and tissue samples to see how certain immune cells behave. The goal is to find new ways to measure immune suppression, which could h…

This early-stage trial enrolls 16 adults with recurrent IDH-mutant gliomas who are scheduled for surgery. Participants take niraparib for one month before their operation so researchers can measure how much drug reaches the tumor and how it affects cancer cells. The goal is to ga…